
PepGen Inc (PEPG) Stock Forecast & Price Target
PepGen Inc (PEPG) Analyst Ratings
Bulls say
PepGen is a clinical-stage biotechnology company that holds significant potential in the world of oligonucleotide therapeutics. With its Enhanced Delivery Oligonucleotide platform and pipeline products like PGN-EDO51 and PGN-EDODM1, PepGen has created a robust infrastructure to target various neuromuscular and neurologic diseases. With completion of recruitment in the 10mg/kg multi-dose cohort in the FREEDOM2 study, PepGen is poised to have a successful second half of 2026 and could potentially meet or exceed market expectations. The company has also shown promising data in terms of drug concentrations and splicing correction, but it will be important to monitor functional assessments and safety updates in the future. Overall, PepGen's promising pipeline and potential to meet unmet medical needs make it a strong investment opportunity for the future.
Bears say
PepGen is a clinical-stage biotechnology company with a promising Enhanced Delivery Oligonucleotide platform, but concerns remain around their PGN-EDODM1 drug and its splicing data, as seen in previous presentations. The company has experienced delays in potential commercial launches and needs to access external funding for their development platform. Safety concerns also need to be thoroughly addressed, as higher dosing data from their FREEDOM-2 cohort in the second half of 2026 will shed important insights into the PGN-EDODM1 safety and efficacy profile. With the company's current financial status and safety concerns, we have a negative outlook on PepGen's stock.
This aggregate rating is based on analysts' research of PepGen Inc and is not a guaranteed prediction by Public.com or investment advice.
PepGen Inc (PEPG) Analyst Forecast & Price Prediction
Start investing in PepGen Inc (PEPG)
Order type
Buy in
Order amount
Est. shares
0 shares